COVID-19 and kidney transplantation

IF 3.2 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Presse Medicale Pub Date : 2022-12-01 DOI:10.1016/j.lpm.2022.104146

Sophie Caillard , French Registry of Solid Organ Transplant Patients COVID-19

{"title":"COVID-19 and kidney transplantation","authors":"Sophie Caillard , French Registry of Solid Organ Transplant Patients COVID-19","doi":"10.1016/j.lpm.2022.104146","DOIUrl":null,"url":null,"abstract":"<div><p>The COVID-19 pandemic affects the transplant recipients since March 2020. Transplant centers quickly organized themselves to optimize the management of the immunocompromised patients and to progress in the knowledge of this new disease. To this end, a French Registry was created, which includes all solid organ transplant patients who have developed a SARS Cov2 infection. Numerous studies have been carried out using these data to describe this new disease in transplant patients, to characterize its clinical and biological risk factors and to define its prognosis. The 60 days-mortality of transplant patients hospitalized for COVID-19 was evaluated at 23% and renal failure plays a major role in the poor prognosis in addition to the classical risk factors described in the general population. The advent of vaccination has been a great relief but transplanted patients have shown a poor vaccine response keeping them at risk of severe disease even after an adapted vaccination scheme. Specific strategies was proposed in this particularly fragile population like increasing vaccine doses or using anti SARS Cov-2 monoclonal antibodies.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":"51 4","pages":"Article 104146"},"PeriodicalIF":3.2000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636029/pdf/","citationCount":"621","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Presse Medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0755498222000392","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 621

Abstract

The COVID-19 pandemic affects the transplant recipients since March 2020. Transplant centers quickly organized themselves to optimize the management of the immunocompromised patients and to progress in the knowledge of this new disease. To this end, a French Registry was created, which includes all solid organ transplant patients who have developed a SARS Cov2 infection. Numerous studies have been carried out using these data to describe this new disease in transplant patients, to characterize its clinical and biological risk factors and to define its prognosis. The 60 days-mortality of transplant patients hospitalized for COVID-19 was evaluated at 23% and renal failure plays a major role in the poor prognosis in addition to the classical risk factors described in the general population. The advent of vaccination has been a great relief but transplanted patients have shown a poor vaccine response keeping them at risk of severe disease even after an adapted vaccination scheme. Specific strategies was proposed in this particularly fragile population like increasing vaccine doses or using anti SARS Cov-2 monoclonal antibodies.

Abstract Image

查看原文本刊更多论文

COVID-19与肾移植

自2020年3月以来，COVID-19大流行影响了移植接受者。移植中心迅速组织起来，优化免疫功能低下患者的管理，并在这种新疾病的知识方面取得进展。为此，法国建立了一个登记处，其中包括所有感染SARS冠状病毒的实体器官移植患者。利用这些数据进行了大量研究，以描述移植患者的这种新疾病，确定其临床和生物学危险因素，并确定其预后。因COVID-19住院的移植患者的60天死亡率评估为23%，除一般人群中描述的经典危险因素外，肾功能衰竭在预后不良中起主要作用。疫苗接种的出现是一种极大的缓解，但移植患者表现出较差的疫苗反应，使他们即使在经过调整的疫苗接种方案后仍有严重疾病的风险。针对这一特别脆弱的人群提出了具体的策略，如增加疫苗剂量或使用抗SARS Cov-2单克隆抗体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Presse Medicale 医学-医学：内科

自引率

3.70%

发文量

审稿时长

43 days

期刊介绍： Seule revue médicale "généraliste" de haut niveau, La Presse Médicale est l''équivalent francophone des grandes revues anglosaxonnes de publication et de formation continue. A raison d''un numéro par mois, La Presse Médicale vous offre une double approche éditoriale : - des publications originales (articles originaux, revues systématiques, cas cliniques) soumises à double expertise, portant sur les avancées médicales les plus récentes ; - une partie orientée vers la FMC, vous propose une mise à jour permanente et de haut niveau de vos connaissances, sous forme de dossiers thématiques et de mises au point dans les principales spécialités médicales, pour vous aider à optimiser votre formation.